These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 24612551

  • 1. Treatment of ankylosing spondylitis with TNF inhibitors does not have adverse effect on results of liver function tests: a longitudinal study.
    Capkin E, Karkucak M, Cosar AM, Ak E, Karaca A, Gokmen F, Budak BS, Tosun M.
    Int J Rheum Dis; 2015 Jun; 18(5):548-52. PubMed ID: 24612551
    [Abstract] [Full Text] [Related]

  • 2. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
    Ciurea A, Scherer A, Weber U, Exer P, Bernhard J, Tamborrini G, Riek M, Müller RB, Weiss B, Nissen MJ, Kissling R, Michel BA, Finckh A, Rheumatologists of Swiss Clinical Quality Management Program for Axial Spondyloarthritis.
    Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
    [Abstract] [Full Text] [Related]

  • 3. Comparative Efficacy of Tumor Necrosis Factor-α Inhibitors in Ankylosing Spondylitis: A Systematic Review and Bayesian Network Metaanalysis.
    Wang R, Dasgupta A, Ward MM.
    J Rheumatol; 2018 Apr; 45(4):481-490. PubMed ID: 29335342
    [Abstract] [Full Text] [Related]

  • 4. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
    Perrotta FM, Addimanda O, Ramonda R, D'Angelo S, Lubrano E, Marchesoni A, Olivieri I, Punzi L, Salvarani C, Spadaro A.
    Reumatismo; 2014 Nov 06; 66(3):208-14. PubMed ID: 25376955
    [Abstract] [Full Text] [Related]

  • 5. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
    de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, Hazenberg BP, Wolbink GJ.
    Arthritis Rheum; 2009 Nov 15; 61(11):1484-90. PubMed ID: 19877087
    [Abstract] [Full Text] [Related]

  • 6. Spectral domain-optical coherence tomographic findings in patients with ankylosing spondylitis under anti-tumor necrosis factor-alpha therapy.
    Ilhan N, Ustun N, Tuzcu EA, Coskun M, Yagiz AE, Ilhan O, Parlakfikirer N.
    Cutan Ocul Toxicol; 2015 Nov 15; 34(3):222-6. PubMed ID: 25363064
    [Abstract] [Full Text] [Related]

  • 7. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH, Huang F, Deng XH, Zhang JL, Zhang LY, Guo JH, Liang DF, Wang LS, Zhang YM.
    Zhonghua Yi Xue Za Zhi; 2006 Sep 19; 86(35):2451-4. PubMed ID: 17156669
    [Abstract] [Full Text] [Related]

  • 8. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
    Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Th A Jansen TL, Kallenberg CG, Spoorenberg A.
    Arthritis Res Ther; 2011 Jun 20; 13(3):R94. PubMed ID: 21689401
    [Abstract] [Full Text] [Related]

  • 9. Ankylosing Spondylitis Response to TNF Inhibition Is Gender Specific: A 6-Year Cohort Study.
    Murray C, Fearon C, Dockery M, Moran D, Heffernan E, Fitzgerald O, Veale DJ, Harty L.
    Ir Med J; 2018 Oct 11; 111(9):820. PubMed ID: 30556668
    [Abstract] [Full Text] [Related]

  • 10. Tumor necrosis factor-α promoter -308/238 polymorphism association with less severe disease in ankylosing spondylitis is unrelated to serum TNF-α and does not predict TNF inhibitor response.
    Nossent JC, Sagen-Johnsen S, Bakland G.
    J Rheumatol; 2014 Aug 11; 41(8):1675-82. PubMed ID: 25028373
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of the frequency and intensity of COVID-19 in patients with ankylosing spondylitis under anti-TNF therapy.
    Türk SM, Öztürk Z, Karataş D, Erkorkmaz Ü, Gönüllü E.
    Turk J Med Sci; 2022 Apr 11; 52(2):522-523. PubMed ID: 36161620
    [Abstract] [Full Text] [Related]

  • 12. Tumor Necrosis Factor-α Inhibition in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Treatment Response, Drug Survival, and Patient Outcome.
    Corli J, Flipo RM, Philippe P, Bera-Louville A, Béhal H, Wibaux C, Paccou J.
    J Rheumatol; 2015 Dec 11; 42(12):2376-82. PubMed ID: 26568593
    [Abstract] [Full Text] [Related]

  • 13. Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.
    Wallman JK, Kapetanovic MC, Petersson IF, Geborek P, Kristensen LE.
    Arthritis Res Ther; 2015 Dec 24; 17():378. PubMed ID: 26703005
    [Abstract] [Full Text] [Related]

  • 14. Continuous Improvement of Physical Functioning in Ankylosing Spondylitis Patients by Tumor Necrosis Factor Inhibitors: Three-Year Followup and Predictors.
    van Weely SF, Kneepkens EL, Nurmohamed MT, Dekker J, van der Horst-Bruinsma IE.
    Arthritis Care Res (Hoboken); 2016 Oct 24; 68(10):1522-9. PubMed ID: 26881893
    [Abstract] [Full Text] [Related]

  • 15. Predictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing Spondylitis.
    Lee JW, Kang JH, Yim YR, Kim JE, Wen L, Lee KE, Park DJ, Kim TJ, Park YW, Lee SS.
    PLoS One; 2015 Oct 24; 10(7):e0131864. PubMed ID: 26176701
    [Abstract] [Full Text] [Related]

  • 16. Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice.
    Escudero-Vilaplana V, Ramírez-Herráiz E, Alañón-Plaza E, Trovato-López N, García-Vicuña R, Carreño-Pérez L, Morell-Baladrón A, Sanjurjo-Sáez M.
    Int J Clin Pharm; 2015 Oct 24; 37(5):808-14. PubMed ID: 25910480
    [Abstract] [Full Text] [Related]

  • 17. Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis.
    Gulyas K, Bodnar N, Nagy Z, Szamosi S, Horvath A, Vancsa A, Vegh E, Szabo Z, Szucs G, Szekanecz Z, Szanto S.
    Eur J Health Econ; 2014 May 24; 15 Suppl 1():S93-100. PubMed ID: 24832840
    [Abstract] [Full Text] [Related]

  • 18. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG, Pontikaki I, Becciolini A, Biggioggero M, Ughi N, Romano M, Crotti C, Gattinara M, Gerloni V, Marchesoni A, Meroni PL.
    Clin Rheumatol; 2017 Aug 24; 36(8):1747-1755. PubMed ID: 28597133
    [Abstract] [Full Text] [Related]

  • 19. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry.
    Glintborg B, Østergaard M, Krogh NS, Tarp U, Manilo N, Loft AG, Hansen A, Schlemmer A, Fana V, Lindegaard HM, Nordin H, Rasmussen C, Ejstrup L, Jensen DV, Petersen PM, Hetland ML.
    Ann Rheum Dis; 2013 Jul 24; 72(7):1149-55. PubMed ID: 22941767
    [Abstract] [Full Text] [Related]

  • 20. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
    Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Sieper J.
    Rheumatology (Oxford); 2005 May 24; 44(5):670-6. PubMed ID: 15757965
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.